Javascript must be enabled to continue!
The First Insight into the Hereditary Fusion Gene Landscape of Amyotrophic Lateral Sclerosis
View through CrossRef
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive nervous system disease that causes loss of muscle control. Over 30 mutated genes are associated with ASL. However, 90-95% of ASL cases have been found without a family history. Here, we have analyzed RNA-Seq data of NYGC ALS Consortium and identified fusion transcripts from ASL patients and non-neurologic controls (NNC). In this study, we combined previously-curated 1180 monozygotic (MZ) hereditary fusion genes (HFGs), and 204 HFGs discovered from NNC to analyze ASL fusion transcripts and identified 348 HFGs. Comparative analysis between ASL and GTEx shows that 139 HFGs are associated with ASL and ranged from 10.4% to 98.7% of 77 ASL patients. The most recurrent HFG is
ZNF528-ZNF880
, detected in 98.7% of 77 ASL patients and 4.5% of 133 GTEx brain cortexes. Alignments of HFG transcripts from ASL with fusion transcripts from mesial temporal lobe epilepsy (MTLE) and Alzheimer’s disease (AD) showed that 43.9% and 11.6% of the ASL HFGs were present in MTLE and AD, respectively. The most recurrent and common HFG among ASL, MTLE, and AD was
ADAMTSL3-SH3GL3
, which behaves like ubiquitously-expressed
SH3GL3-ADAMTSL3
epigenetic fusion gene (EFG) and shows that
ADAMTSL3-SH3GL3
is a potential dormant or differentially-expressed HFG (dHFG), suggesting that they have common pathophysiological mechanisms. These HFGs associated with ASL have shown that HFGs are the missing genetic heritability and provide novel therapeutic targets for more efficient therapeutic drugs and methods to treat and cure many neurological diseases.
Title: The First Insight into the Hereditary Fusion Gene Landscape of Amyotrophic Lateral Sclerosis
Description:
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive nervous system disease that causes loss of muscle control.
Over 30 mutated genes are associated with ASL.
However, 90-95% of ASL cases have been found without a family history.
Here, we have analyzed RNA-Seq data of NYGC ALS Consortium and identified fusion transcripts from ASL patients and non-neurologic controls (NNC).
In this study, we combined previously-curated 1180 monozygotic (MZ) hereditary fusion genes (HFGs), and 204 HFGs discovered from NNC to analyze ASL fusion transcripts and identified 348 HFGs.
Comparative analysis between ASL and GTEx shows that 139 HFGs are associated with ASL and ranged from 10.
4% to 98.
7% of 77 ASL patients.
The most recurrent HFG is
ZNF528-ZNF880
, detected in 98.
7% of 77 ASL patients and 4.
5% of 133 GTEx brain cortexes.
Alignments of HFG transcripts from ASL with fusion transcripts from mesial temporal lobe epilepsy (MTLE) and Alzheimer’s disease (AD) showed that 43.
9% and 11.
6% of the ASL HFGs were present in MTLE and AD, respectively.
The most recurrent and common HFG among ASL, MTLE, and AD was
ADAMTSL3-SH3GL3
, which behaves like ubiquitously-expressed
SH3GL3-ADAMTSL3
epigenetic fusion gene (EFG) and shows that
ADAMTSL3-SH3GL3
is a potential dormant or differentially-expressed HFG (dHFG), suggesting that they have common pathophysiological mechanisms.
These HFGs associated with ASL have shown that HFGs are the missing genetic heritability and provide novel therapeutic targets for more efficient therapeutic drugs and methods to treat and cure many neurological diseases.
Related Results
Determinants of lateral fusion in single-level oblique lateral lumbar interbody fusion: a retrospective analysis of fusion patterns and clinical outcomes
Determinants of lateral fusion in single-level oblique lateral lumbar interbody fusion: a retrospective analysis of fusion patterns and clinical outcomes
Study Design: Retrospective cohort study.Purpose: This study aimed to (1) determine the incidence of lateral fusion following single-level oblique lateral interbody fusion (OLIF); ...
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Abstract
Amyotrophic lateral sclerosis is a progressive neurodegenerative syndrome characterized by loss of motor neurons. Cognit...
The Nuclear Fusion Award
The Nuclear Fusion Award
The Nuclear Fusion Award ceremony for 2009 and 2010 award winners was held during the 23rd IAEA Fusion Energy Conference in Daejeon. This time, both 2009 and 2010 award winners w...
Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration
Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration
Abstract
TDP-43 is mislocalized from the nucleus and aggregates within the cytoplasm of affected neurons in cases of amyotrophic lateral sclerosis. TDP-43 pathology ...
Amyotrophic lateral sclerosis: Neural repair strategies based on multi-target synchronous interventions
Amyotrophic lateral sclerosis: Neural repair strategies based on multi-target synchronous interventions
Abstract
Amyotrophic lateral sclerosis is a progressive and fatal neurodegenerative disease that targets motor neurons in the cerebral cortex, medulla oblongata, ...
An open-label Phase 2a study to assess the safety and tolerability of trimetazidine in patients with amyotrophic lateral sclerosis
An open-label Phase 2a study to assess the safety and tolerability of trimetazidine in patients with amyotrophic lateral sclerosis
Abstract
Metabolic imbalance is associated with amyotrophic lateral sclerosis progression. Impaired glucose oxidation and increased reliance on fatty acid oxidation ...
Genetic aspects of amyotrophic lateral sclerosis
Genetic aspects of amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis is a progressive, incurable neurodegenerative disease characterized by motor neuron loss and the development of paralysis and skeletal muscle atrophy....
Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations
Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations
Abstract
Amyotrophic lateral sclerosis is a relentless neurodegenerative disease that is mostly fatal within 3–5 years and is diagnosed on evidence of progressive up...

